Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab176456-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $129.90 | |
| Ab176456-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $649.90 | |
| Ab176456-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $1,629.90 | |
| Ab176456-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,609.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Apamistamab (anti-PTPRC) - Primary antibody, specific to PTPRC, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | B220 antibody; CD 45 antibody; CD45 antibody; CD45 antigen antibody; CD45R antibody; GP180 antibody; L-CA antibody; LCA antibody; Leukocyte common antigen antibody; loc antibody; Ly-5 antibody; LY5 antibody; Ly5, homolog of antibody; Lyt-4 antibody; OTTHU |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | PTPRC |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description | Apamistamab (anti-PTPRC) is an anti-CD45 monoclonal antibody (MoAb) with immunotherapeutic activity. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 28.0 kDa (Light Chain) & 52.1 kDa (Heavy Chain), under reducing conditions; 198.5 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 2097132-02-8 |
Apamistamab (anti-PTPRC) (Ab176456) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling PTPRC with Apamistamab (anti-PTPRC) (Ab176456) conjugated with biotin (right panel) compared with Human IgG (Ab170213) conjugated with biotin - Isotype Control (left panel) and detected with SA-PE (rp156250).
Apamistamab (anti-PTPRC) (Ab176456) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling PTPRC (red) with Apamistamab (anti-PTPRC) (Ab176456) conjugated with biotin and detected with SA-PE (rp156250). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.
Apamistamab (anti-PTPRC) (Ab176456) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling PTPRC (red) with Apamistamab (anti-PTPRC) (Ab176456). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Apamistamab (anti-PTPRC) (Ab176456) - SEC
The purity of Apamistamab (anti-PTPRC) (Ab176456) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1001523 | Certificate of Analysis | Nov 02, 2023 | Ab176456 |
| ZJ23F1001522 | Certificate of Analysis | Nov 02, 2023 | Ab176456 |
| 1. He Y, Liu S, Menon A, Stanford S, Oppong E, Gunawan AM, Wu L, Wu DJ, Barrios AM, Bottini N et al.. (2013) A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases.. J Med Chem, 56 (12): (4990-5008). [PMID:23713581] |
| 2. Yu X, Sun JP, He Y, Guo X, Liu S, Zhou B, Hudmon A, Zhang ZY. (2007) Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.. Proc Natl Acad Sci USA, 104 (50): (19767-72). [PMID:18056643] |
| 3. Stanford SM, Krishnamurthy D, Falk MD, Messina R, Debnath B, Li S, Liu T, Kazemi R, Dahl R, He Y et al.. (2011) Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells.. J Med Chem, 54 (6): (1640-54). [PMID:21341673] |
| 4. Katherine A Rawls,P Therese Lang,Jun Takeuchi,Shinichi Imamura,Tyler D Baguley,Christoph Grundner,Tom Alber,Jonathan A Ellman. (2009-11-06) Fragment-based discovery of selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA.. Bioorganic & medicinal chemistry letters, 19 ((24)): (6851-6854). [PMID:19889539] |
| 5. Dufresne C, Roy P, Wang Z, Asante-Appiah E, Cromlish W, Boie Y, Forghani F, Desmarais S, Wang Q, Skorey K, Waddleton D, Ramachandran C, Kennedy BP, Xu L, Gordon R, Chan CC, Leblanc Y.. (2004) The development of potent non-peptidic PTP-1B inhibitors.. Bioorg Med Chem Lett, 14 (4): (1039-1042). [PMID:15013019] |
| 6. Chen YT, Seto CT.. (2002) Divalent and trivalent alpha-ketocarboxylic acids as inhibitors of protein tyrosine phosphatases.. J Med Chem, 45 (18): (3946-3952). [PMID:12190316] |
| 7. Andersen HS, Olsen OH, Iversen LF, Sørensen AL, Mortensen SB, Christensen MS, Branner S, Hansen TK, Lau JF, Jeppesen L, Moran EJ, Su J, Bakir F, Judge L, Shahbaz M, Collins T, Vo T, Newman MJ, Ripka WC, Møller NP.. (2002) Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B.. J Med Chem, 45 (20): (4443-4459). [PMID:12238924] |
| 8. Wilson DP, Wan ZK, Xu WX, Kirincich SJ, Follows BC, Joseph-McCarthy D, Foreman K, Moretto A, Wu J, Zhu M, Binnun E, Zhang YL, Tam M, Erbe DV, Tobin J, Xu X, Leung L, Shilling A, Tam SY, Mansour TS, Lee J.. (2007) Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site.. J Med Chem, 50 (19): (4681-4698). [PMID:17705360] |
| 9. Han Y, Belley M, Bayly CI, Colucci J, Dufresne C, Giroux A, Lau CK, Leblanc Y, McKay D, Therien M, Wilson MC, Skorey K, Chan CC, Scapin G, Kennedy BP.. (2008) Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor.. Bioorg Med Chem Lett, 18 (11): (3200-3205). [PMID:18477508] |
| 10. Cosconati S, Hong JA, Novellino E, Carroll KS, Goodsell DS, Olson AJ.. (2008) Structure-based virtual screening and biological evaluation of Mycobacterium tuberculosis adenosine 5'-phosphosulfate reductase inhibitors.. J Med Chem, 51 (21): (6627-6630). [PMID:18855373] |
| 11. Yu WM, Guvench O, Mackerell AD, Qu CK.. (2008) Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay.. J Med Chem, 51 (23): (7396-7404). [PMID:19007293] |
| 12. Vidović D, Schürer SC.. (2009) Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design.. J Med Chem, 52 (21): (6649-6659). [PMID:19810703] |
| 13. Wu S, Vossius S, Rahmouni S, Miletic AV, Vang T, Vazquez-Rodriguez J, Cerignoli F, Arimura Y, Williams S, Hayes T, Moutschen M, Vasile S, Pellecchia M, Mustelin T, Tautz L.. (2009) Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells.. J Med Chem, 52 (21): (6716-6723). [PMID:19888758] |
| 14. Zhang X, He Y, Liu S, Yu Z, Jiang ZX, Yang Z, Dong Y, Nabinger SC, Wu L, Gunawan AM, Wang L, Chan RJ, Zhang ZY.. (2010) Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).. J Med Chem, 53 (6): (2482-2493). [PMID:20170098] |
| 15. Vang T, Xie Y, Liu WH, Vidović D, Liu Y, Wu S, Smith DH, Rinderspacher A, Chung C, Gong G, Mustelin T, Landry DW, Rickert RC, Schürer SC, Deng SX, Tautz L.. (2011) Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.. J Med Chem, 54 (2): (562-571). [PMID:21190368] |
| 16. Yu ZH, Chen L, Wu L, Liu S, Wang L, Zhang ZY.. (2011) Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening.. Bioorg Med Chem Lett, 21 (14): (4238-4242). [PMID:21669525] |
| 17. He Y, Xu J, Yu ZH, Gunawan AM, Wu L, Wang L, Zhang ZY.. (2013) Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold.. J Med Chem, 56 (3): (832-842). [PMID:23305444] |
| 18. Liu W, Yu B, Xu G, Xu WR, Loh ML, Tang LD, Qu CK.. (2013) Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).. J Med Chem, 56 (18): (7212-7221). [PMID:23957426] |
| 19. Baguley TD, Xu HC, Chatterjee M, Nairn AC, Lombroso PJ, Ellman JA.. (2013) Substrate-based fragment identification for the development of selective, nonpeptidic inhibitors of striatal-enriched protein tyrosine phosphatase.. J Med Chem, 56 (19): (7636-7650). [PMID:24083656] |
| 20. Tautz L, Senis YA, Oury C, Rahmouni S.. (2015) Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.. Bioorg Med Chem, 23 (12): (2786-2797). [PMID:25921264] |
| 21. He R, Bai Y, Yu ZH, Wu L, Gunawan AM, Zhang ZY.. (2014) Diversity-Oriented Synthesis for Novel, Selective and Drug-like Inhibitors for a Phosphatase from Mycobacterium Tuberculosis.. Medchemcomm, 5 (10): (1496-1499). [PMID:25505942] |
| 22. Haftchenary S, Jouk AO, Aubry I, Lewis AM, Landry M, Ball DP, Shouksmith AE, Collins CV, Tremblay ML, Gunning PT.. (2015) Identification of Bidentate Salicylic Acid Inhibitors of PTP1B.. ACS Med Chem Lett, 6 (9): (982-986). [PMID:26396684] |
| 23. Li Y, Xia G, Guo Q, Wu L, Chen S, Yang Z, Wang W, Zhang ZY, Zhou X, Jiang ZX.. (2016) Design, synthesis and evaluation of novel 19F magnetic resonance sensitive protein tyrosine phosphatase inhibitors.. Medchemcomm, 7 (8): (1672-1680). [PMID:27529021] |
| 24. Abdjul DB, Yamazaki H, Kanno SI, Wewengkang DS, Rotinsulu H, Sumilat DA, Ukai K, Kapojos MM, Namikoshi M.. (2017) Furanoterpenes, new types of protein tyrosine phosphatase 1B inhibitors, from two Indonesian marine sponges, Ircinia and Spongia spp.. Bioorg Med Chem Lett, 27 (5): (1159-1161). [PMID:28189419] |
| 25. He R,Wang J,Yu ZH,Zhang RY,Liu S,Wu L,Zhang ZY. (2016) Inhibition of Low Molecular Weight Protein Tyrosine Phosphatase by an Induced-Fit Mechanism.. J Med Chem, 59 (19.0): (9094-9106). [PMID:27676368] |
| 26. Streuli, M M, Krueger, N X NX, Thai, T T, Tang, M M and Saito, H H.. (1990) Distinct functional roles of the two intracellular phosphatase like domains of the receptor-linked protein tyrosine phosphatases LCA and LAR.. The EMBO journal, [PMID:1695146] |
| 27. Tsai, A Y AY, Streuli, M M and Saito, H H.. (1989) Integrity of the exon 6 sequence is essential for tissue-specific alternative splicing of human leukocyte common antigen pre-mRNA.. Molecular and cellular biology, [PMID:2531281] |
| 28. Streuli, M M, Hall, L R LR, Saga, Y Y, Schlossman, S F SF and Saito, H H.. (1987) Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens.. The Journal of experimental medicine, (1): [PMID:2824653] |
| 29. Charbonneau, H H, Tonks, N K NK, Walsh, K A KA and Fischer, E H EH.. (1988) The leukocyte common antigen (CD45): a putative receptor-linked protein tyrosine phosphatase.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2845400] |
| 30. Ralph, S J SJ, Thomas, M L ML, Morton, C C CC and Trowbridge, I S IS.. (1987) Structural variants of human T200 glycoprotein (leukocyte-common antigen).. The EMBO journal, [PMID:2956090] |
| 31. Hall, L R LR, Streuli, M M, Schlossman, S F SF and Saito, H H.. (1988) Complete exon-intron organization of the human leukocyte common antigen (CD45) gene.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:2971730] |
| 32. Kung, C C and 12 more authors.. (2000) Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease.. Nature medicine, [PMID:10700239] |
| 33. Jacobsen, M M and 15 more authors.. (2000) A point mutation in PTPRC is associated with the development of multiple sclerosis.. Nature genetics, [PMID:11101853] |
| 34. Tchilian, E Z EZ and 5 more authors.. (2001) A deletion in the gene encoding the CD45 antigen in a patient with SCID.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:11145714] |
| 35. Wu, Liangtang L, Fu, Jun J and Shen, Shi-Hsiang SH.. (2002) SKAP55 coupled with CD45 positively regulates T-cell receptor-mediated gene transcription.. Molecular and cellular biology, [PMID:11909961] |
| 36. Fukuhara, Kenjiro K and 6 more authors.. (2002) A study on CD45 isoform expression during T-cell development and selection events in the human thymus.. Human immunology, [PMID:11975983] |
| 37. Nam, Hyun-Joo HJ, Poy, Florence F, Saito, Haruo H and Frederick, Christin A CA.. (2005) Structural basis for the function and regulation of the receptor protein tyrosine phosphatase CD45.. The Journal of experimental medicine, (7): [PMID:15684325] |
| 38. Panchal, Rekha G RG and 10 more authors.. (2009) Reduced expression of CD45 protein-tyrosine phosphatase provides protection against anthrax pathogenesis.. The Journal of biological chemistry, (8): [PMID:19269962] |
| 39. Wollscheid, Bernd B and 7 more authors.. (2009) Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins.. Nature biotechnology, [PMID:19349973] |
| 40. Gabaev, Ildar I and 9 more authors.. (2011) The human cytomegalovirus UL11 protein interacts with the receptor tyrosine phosphatase CD45, resulting in functional paralysis of T cells.. PLoS pathogens, [PMID:22174689] |
| 41. Roberts, Joseph L JL and 12 more authors.. (2012) CD45-deficient severe combined immunodeficiency caused by uniparental disomy.. Proceedings of the National Academy of Sciences of the United States of America, (26): [PMID:22689986] |
